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Activation of 5-fluorouracil into its nucleotides requires phosphorylation by three pathways involving orotate phosphoribosyl-
transferase (OPRT), uridine phosphorylase (UP), or thymidine phosphorylase (TP). In this study, we investigated the association
between gene expressions of these three enzymes and antitumour effect. Gene expressions in primary colorectal tumours were
analysed by a real-time reverse transcriptional–polymerase chain reaction method in 37 patients receiving oral treatment of tegafur-
uracil and leucovorin for metastatic diseases. The median values of OPRT mRNA expressions were 1.39 and 0.85 for responding
tumours and nonresponding tumours, respectively, showing a statistically significant difference (P¼0.0008). Responding tumours had
statistically lower expressions of TP mRNA than nonresponding tumours (P¼0.006). However, there was no difference in UP
mRNA expression between responding and nonresponding tumours. Patients with high OPRT (X1.0) gene expression survived
longer than those with low OPRT (o1.0) expression. Dihydropyrimidine dehydrogenase (DPD) gene expressions were measured.
Responding tumours had a statistically higher OPRT/DPD ratio than the nonresponding ones (P¼0.003). When the median value of
the OPRT/DPD ratio was selected as the cutoff value, patients with a high OPRT/DPD ratio survived statistically longer than those
with a low ratio (P¼0.0014). In conclusion, both the expression of OPRT gene and the OPRT/DPD ratio might be useful as
predictive parameters for the efficacy of fluoropyrimidine-based chemotherapy for metastatic colorectal cancer.
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An important anticancer agent widely used in the treatment of
colorectal cancers, 5-fluorouracil (5-FU), is catabolised rapidly to
the inactive metabolite dihydrofluorouracil (FUH2) by the first and
rate-limiting enzyme-dihydropyrimidine dehydrogenase (DPD)
(Heggie et al, 1987). The main mode of action of 5-FU is thought
to be through its active metabolite: 5-fluoro-uridine-50-tripho-
sphate (FUTP) or 5-fluoro-20-deoxyuridine-50-monophosphate
(FdUMP) (Danenberg, 1977). Metabolites such as FUTP can be
incorporated into RNA, while FdUMP suppresses thymidylate
synthase (TS), an essential DNA de novo synthetic enzyme that
catalyses the methylation of deoxyuridine monophosphate
(dUMP) to deoxythymidine monophosphate (dTMP) (Danenberg,
1977; Pinedo and Peters, 1988).
With combined DPD and TS gene expressions, both response
and survival could be predicted more precisely than on the bases
of only one gene expression. No tumour with both high DPD and
high TS expression responded to tegafur-uracil (UFT), an oral
fluoropyrimidine, and leucovorin (LV) therapy, but not even all
tumours with both low DPD and low TS expression responded to
the therapy, such cases having a response rate of 75% (Ichikawa
et al, 2003). Salonga et al (2000) reported that only one of 12
tumours with both low DPD and low TS expression was a
nonresponder to 5-FU, but that case had a high thymidine
phosphorylase (TP) expression. These data suggested that
combined evaluation of other gene expressions is needed to
predict response more accurately.
While the importance of the value of DPD and TS for
antitumour effects is recognised, the contribution of the different
pathways to 5-FU activation is still unclear. Phosphorylation is
necessary to activate 5-FU into its nucleotides by one or more of
the following three pathways: (1) pathway 1: directly to FUMP by
orotate phosphoribosyltransferase (OPRT) in the presence of 5-
phosphoribosyl-1-pyrophosphate (PRPP); (2) pathway 2: indir-
ectly to FUMP in a sequence of reactions with conversion of 5-FU
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yto 5-fluorouridine (FUR) catabolised by uridine phosphorylase
(UP) in the presence of ribose-1-phosphate (Rib-1-P); (3) pathway
3: indirectly to FdUMP by 20-deoxy-5-fluorouridine (FUdR)
catalysed by TP in the presence of deoxyribose-1-phosphate
(dRib-1-P) (Figure 1) (Peters et al, 1986, 1991).
The preferential use of the OPRT pathway (Pathway 1) was
revealed to correlate with a higher sensitivity to 5-FU in cell lines
and human xenograft models (Peters et al, 1986, 1991). Recently,
in studies using human colorectal cancer tissues, a higher OPRT
enzyme activity was observed in 5-FU-sensitive tissues than
nonsensitive ones in in vitro chemosensitivity test (Isshi et al,
2002; Fujii et al, 2003). However, some investigators stated that the
UP pathway (Pathway 2) is critical in the activation of 5-FU in
experimental models (Schwartz et al, 1985; Cao et al, 2002). It is
still controversial as to whether OPRT or UP gene expression is a
key enzyme to activate 5-FU to predict the antitumour effect in the
clinical setting.
Increasing TP activity is associated with the use of inter-
feron (Evans et al, 1981), pyrimidine analogues (Schwartz et al,
1995; Ciccolini et al, 2000), or direct transfection of the TP gene
(Evrard et al, 1999) to various cell lines and human xenograft
models, which results in an increase in sensitivity to 5-FU.
However, in the clinical setting, a high baseline level of gene
expression of TP in colorectal tumours was associated with
nonresponse in 5-FU/LV therapy (Metzger et al, 1998; Salonga et al,
2000). It is as yet unclear whether tumoral TP expression
affects the antitumour effect of UFT/LV therapy on metastatic
colorectal cancer.
In this study, we evaluated the predictive values of gene
expressions of three phosphorylating enzymes, OPRT, UP, and TP,
in UFT/LV treatment for metastatic colorectal cancer. In addition,
the gene expression ratio of 5-FU-phosphorylating enzymes and
the 5-FU degenerating enzyme DPD was also investigated for
comparison with the antitumour effect, such as tumour shrinkage
and survival.
PATIENTS AND METHODS
Clinical methods
The study population consisted of 37 patients with metastatic
colorectal cancer, treated from July 1998 to December 2000 at the
Department of Digestive Surgery, Tokyo Medical and Dental
University, Tokyo, Japan. This study was approved by the
Institutional Review Board of Tokyo Medical and Dental
University, and all patients gave written informed consent.
These 37 cases represent all patients during that period who
satisfied our enrollment criteria. They received the same treatment
as first-line chemotherapy for metastatic disease, after resection of
the primary tumour. Eligibility criteria, patient characteristics, and
treatment regimens were previously described (Ichikawa et al,
2000, 2003). Eligible patients had (1) a performance status score of
2 or better on the Zubrod scale (Eastern Cooperative Oncology
[ECOG]) (Zubrod et al, 1960); (2) at least one measurable lesion;
(3) adequate haematological, hepatic, and renal function; (4) life
expectancy over 3 months. The median age was 62 years (range:
38–80 years). Nine patients had synchronous metastatic tumours
at the time of resection of primary tumours and the other 28
patients had metachronous metastasis after resection of the
primary tumours. Treatment consisted of 400mgm
2day
 1 oral
UFT (in two doses q 12h) and 15mgbodyday
 1 LV (in three doses
q 8h) for 5 days, followed by a 2-day rest period for four times
during one 28-day cycle.
Before the treatment and after every two cycles (8 weeks) of
treatment, measurable disease was reassessed by computed
tomography. The response evaluation was based on standard
UICC guidelines (Hayward et al, 1977). There were two complete
responses (CR), 10 partial responses, 16 cases with no change, and
nine cases of progressive disease, with a 32.4% response rate (95%
confidence interval, 18.0–49.8%). All patients in this study are now
off treatment; 36 of the 37 have died from cancer. One patient is
still alive with CR at 23.0 months. The median follow-up time was
14.0 months.
Archival fresh frozen samples were obtained from the primary
colorectal tumours at the time of surgery. No patient had received
5-FU chemotherapy preoperatively. Immediately after resection,
the tumour sample was divided into two equal portions of at least
500mg each, after removal of necrotic tissues. One portion was
fresh frozen in liquid nitrogen until the time of RNA extraction
and the other portion was embedded in paraffin to confirm
histologically that it contained less than 5% contamination of
normal tissue, necrotic tissue, and lymphocytes.
LABORATORY METHODS
Reverse transcriptional–polymerase chain reaction
(RT–PCR)
Total RNA for each sample was isolated using the RNeasy mini kit
(QIAGEN Inc., Chatsworth, CA, USA) according to the manufac-
turer’s instructions (Chomczynski and Sacchi, 1987). For cDNA
synthesis, reverse transcription using 10mg total RNA was
performed in a total volume of 100mg containing 250pmol oligo
(dT)18, 80U of RNasin (Promega, Madison, WI, USA), and 500U
Molony murine leukaemia virus reverse transcriptase (GIBCO
BRL, Gaithersburg, MD, USA), 50mM Tris-HCL (pH 8.3), 75mM
KCl, 3mM MgCl2,1 0 m M dithiothreitol, and 0.5mM deoxynucleo-
tide triphosphate (dNTP) solution.
5′DFUR
Rib-1-P
Pathway 2
UP
FUR
UK
FUMP
FUdR
FdUDP
FdUMP FdUMP
FUDP FUTP F-RNA
TP
Tegafur
P450
5-FU
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PRPP
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dRib-1-P FUH2
F--Ala
DPD
TP TK
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Figure 1 Metabolism of 5-FU, 50DFUR, and Tegafur.
OPRT and OPRT/DPD in metastatic colorectal cancer
W Ichikawa et al
1487
British Journal of Cancer (2003) 89(8), 1486–1492 & 2003 Cancer Research UK
M
o
l
e
c
u
l
a
r
a
n
d
C
e
l
l
u
l
a
r
P
a
t
h
o
l
o
g
yReal-time RT–PCR quantification
Quantitation of cDNAs of the genes of interest and an internal
reference gene glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) was carried out using a fluorescence-based real-time
detection method (ABI PRISM 7700 Sequence Detection System
(Taqman); Perkin-Elmer Applied Biosystems, Foster City, CA,
USA), as described previously (Gibson et al, 1996; Heid et al, 1996;
Farrugia et al, 2003).
The PCR reaction mixture consisted of 600nM of each primer,
200nM probe, 2.5U of AmpliTaq Gold Polymerase, 200mM each
dATP, dCTP, dGTP, 400mM dTP, 5.5mM MgCl2, and 1  Taqman
Buffer A containing a reference dye, to a final volume of 25ml (all
reagents Perkin-Elmer Applied Biosystems). Cycling conditions
were 501C for 10s, 951C for 10min, followed by 46 cycles at 951C
for 15s and 601C for 1min.
The primers and probe sequences used were as follows: OPRT
primers: TCCTGGGCAGATCTAGTAAATGC and TGCTCCTCAG
CCATTCTAACC, probe 6FAM (carboxyfluorescein)-50-CTCCTTA
TTGCGGAAATGAGCTCCACC-30TAMRA (N,N,N0,N0-tetramethyl-
6-carboxyrhodamine); UP primers: TGACTGCCCAGGTAGAGAC-
TATCC and AGACCTATCCCACCAGAAGTGC, probe 6FAM50-
TGCTCCAACGTCACTATCATCCGCAT-30TAMRA; TP primers:
CCTGCGGACGGAATCCT and GCTGTGATGAGTGGCAGGCT,
probe 6FAM50-CAGCCAGAGATGTGACAGCCACCGT-30TAMRA;
GAPDH primers: GAAGGTGAAGGTCGGAGTC and GAAGATG
GTGATGGGATTTC, probe 6FAM50-CAAGCTTCCCGTTCTCAGC
C-30TAMRA.
Statistical analysis of RT–PCR results
TaqMan analyses yielded values expressed as the ratios between
two absolute measurements (gene of interest/internal reference
gene).
Statistics
The Mann–Whitney U-test was used to compare the responders
and nonresponders in terms of the related gene expressions.
Spearman correlation was used to evaluate the association between
the expressions of two genes. To evaluate the association with
response, a two-sided Fisher’s exact test was used. Survival was
calculated from the onset of chemotherapy until death. One patient
without any event was censored at the date of last follow-up. The
overall survival curve was constructed using the Kaplan-Meier
method, and differences were assessed by the log-rank test.
RESULTS
The relative expressions of OPRT, TP, and UP mRNA were
determined by real-time RT–PCR in 37 primary colorectal cancer
specimens analysed previously for DPD gene expressions (Ichika-
wa et al, 2003). The median values of OPRT, TP, and UP mRNA
expressions were 1.01 (range: 0.42–3.04), 70.0 (range: 10.0–249.8),
and 2.13 (range: 0.56–6.30), respectively.
Tumours were categorised as either responding or not respond-
ing to a regimen of UFT and LV. The median values of OPRT
mRNA expressions were 1.39 (range: 1.02–3.04) and 0.85 (range:
0.42–2.57) for responding tumours and nonresponding tumours,
respectively, with the difference being statistically significant
(P¼0.0008, Mann–Whitney U-test) (Figure 2). The median values
of TP mRNA expressions were 39.3 (range: 10.0–165.6) and 121.6
(range: 25.5–249.8) for responding tumours and nonresponding
tumours, respectively. Responding tumours had statistically lower
expressions of TP mRNA than nonresponding tumours (P¼0.006,
Mann–Whitney U-test) (Figure 2). However, there was no
difference between responding and nonresponding tumours in
UP mRNA expression (median value, 1.73 (range: 0.59–5.56) for
responding tumours vs 2.26 (range: 0.56–6.30) for nonresponding
tumours) (P40.05, Mann–Whitney U-test) (Figure 2).
The median values of 1.0 for OPRT and 70 for TP were selected
for cutoff values separating high and low gene expressions of
OPRT and TP. No responding tumours had low OPRT (o1.0)
mRNA expression (Table 1). A total of 19 tumours had high OPRT
mRNA expressions of more than 1.0, with a corresponding
response rate of 63% (12 out of 19) (Table 1). The response rates
were 17% (three out of 18) and 47% (nine out of 19) in tumours
with high TP (X70) expression and those with low TP (o70)
expression, with a trend in favour of a lower TP mRNA expression
for responding tumours (P¼0.08, the two-sided Fisher’s exact
test) (Table 1).
The median survival was 12.5 months (range: 4.1–28.3 months)
in patients with high OPRT expression, but 8.5 months (range:
3.0–17.3 months) in patients with low expression (P¼0.0019; log-
rank test) (Figure 3). Patients with a low expression of TP mRNA
survived longer than those with a high TP expression (median; 7.4
months ranging from 3.0 to 17.4 months for high expression vs
14.0 months ranging from 7.6 to 28.3 months for low expression,
P¼0.0002; log-rank test) (Figure 3).
Dihydropyrimidine dehydrogenase gene expressions were mea-
sured and the cutoff value for DPD was determined as 0.5, as
previously reported in the same patient population (Ichikawa et al,
2003). A plot of DPD against OPRT mRNA expression showed a
0
1
2
3
O
P
R
T
 
m
R
N
A
N
o
n
r
e
s
p
o
n
d
e
r 0
100
200
300
T
P
 
m
R
N
A
0
2
4
6
U
P
 
m
R
N
A
R
e
s
p
o
n
d
e
r
N
o
n
r
e
s
p
o
n
d
e
r
R
e
s
p
o
n
d
e
r
N
o
n
r
e
s
p
o
n
d
e
r
R
e
s
p
o
n
d
e
r
Figure 2 OPRT, TP, and UP gene expressions in terms of response.
Responding tumours had a statistically higher OPRT gene expression or
lower TP gene expressions than nonresponding tumours (P¼0.0008 for
OPRT and P¼0.006 for TP). There was no difference in UP gene
expression among responding and nonresponding tumours.
Table 1 Summary of response data for tumours with different
expressions of OPRT, TP, and DPD genes
Gene expression status
No. of
responding
patients
No. of
nonresponding
patients P
OPRTX1.0 12 7
OPRTo1.0 0 18 o0.0001
TPX70 3 15
TPo70 9 10 0.08
DPDX0.5 0 18
DPDo0.5 12 7 o0.0001
DPDo0.5 and OPRTX1.0 12 1
DPDX0.5 or OPRTo1.0 0 18 o0.0001
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(Spearman rank correlation coefficient  0.529, P¼0.0015)
(Figure 4). However, six of 19 tumours with low DPD (o0.5)
expression had low OPRT expression, and six of 18 tumours with
high DPD (X0.5) expression had high OPRT expression. In all, 12
of all 13 tumours with both low DPD and high OPRT responded
(response rate: 92%), but no tumours with other combinations
responded (Table 1). The responding tumours had a statistically
higher OPRT/DPD ratio (median values; 4.3 (range: 2.1–20.2))
than nonresponding ones (median values; 1.3 (range: 0.3–4.0))
(P¼0.003, Mann–Whitney U-test) (Figure 5). When the median
value of the OPRT/DPD ratio of 2.1 was selected as the cutoff value,
patients with a high OPRT/DPD ratio (X2.1) survived statistically
longer than those with a low ratio (o2.1) (median; 14.3 months
ranging from 7.4 to 28.3 months for the high ratio vs 8.0 months
ranging from 3.0 to 24.2 months for low expression, P¼0.0014;
log-rank test) (Figure 6).
A plot of DPD against TP mRNA expression showed a positive
correlation between the expressions of these genes (Spearman rank
correlation coefficient 0.520, P¼0.0018) (Figure 4). As previously
reported, there were no responding tumours with high DPD
expression. Among tumours with low DPD expression, the
response rates were not statistically significant between tumours
with a high TP (response rate: 75%) and those with a low TP
(60%). The TP/DPD ratio had no statistical significance in terms of
both response (Figure 5) and survival (data not shown).
DISCUSSION
Our data demonstrate that there was a significant correlation
between the OPRT expression level in tumour, and both the
response and survival in patients treated with UFT and LV. An
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Figure 3 Correlation between prognosis and the expression of OPRT
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Figure 4 DPD expression plotted against OPRT or TP expressions. The
values for DPD expression were obtained from a previously published
study (Ichikawa et al, 2003). Solid and empty circles indicate nonresponders
and responders, respectively. The dotted lines indicate the nonresponse
cutoff values for each gene expression. Dihydropyrimidine dehydrogenase
showed a negative correlation against OPRT expression (r¼ 0.529) and
positive correlation against TP (r¼0.520).
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antitumour effect, and UP gene expression did not affect the
tumour shrinkage and survival. In addition, the gene expression
ratio of OPRT and DPD had a predictive value in the same patient
cohort. This is apparently the first report to indicate a positive
relationship between antitumour effect and OPRT expression in
clinical materials.
In vitro and in vivo studies have shown that the main origin of
TS-directed FdUMP metabolite comes from the reduction of FUDP
by ribonucleotide reductase after prior conversion of FU to FUDP
via OPRT, but not from FUdR phosphorylated by TP (Peters et al,
1986, 1991; Inaba et al, 1996; Koyama et al, 2000). In this study, TP
negatively correlated with the antitumour effect in patients treated
with a UFT and LV regimen, which agrees with previous reports on
5-FU and LV chemotherapy (Metzger et al, 1998; Salonga et al,
2000). Pathway 3 (phosphorylation of 5-FU to FdUMP by FUdR) is
not important for anabolism of 5-FU because of the lack of the TP
cofactor dRib-1-P at physiological concentrations (Barankiewicz
and Henderson, 1977). Conversely, high TP concentrations in
conjunction with the normally low dRib-1-P drive the reaction in
the opposite direction (Ackland and Peters, 1999). These data
support our findings that TP expression is a negative predictor of
the result of treatment with the UFT and LV regimen.
Both TP and DPD are important enzymes in the pyrimidine
salvage pathway (Fujiwaki et al, 2000). In addition, these two
enzymes are associated with tumour aggressiveness. Thymidine
phosphatase, which is identical to platelet-derived endothelial cell
growth factor (Furukawa et al, 1992), and the degeneration
products thymine and 2-deoxy-D-ribose have angiogenic (Ishikawa
et al, 1989) and antiapoptotic effects (Kitazono et al, 1998). In
human colorectal cancer, the DPD mRNA expression level was
associated with a higher pathological classification, corresponding
to the depth of invasion and lymph node metastasis (Shirota et al,
2002). The DPD gene expression of the liver metastasis was
significantly higher than that of primary tumours. Based on these
data, the moderately positive relationship between TP and DPD
gene expressions in human colorectal cancer tissues is not
surprising. Mori et al (2000) also reported that DPD protein
expression strongly correlated with TP protein expression in
colorectal cancer tissues, when measured by the enzyme-linked
immunosorbent assay (ELISA) method (r 0.915, Po0.0001).
Recently, it has been reported that the TP/DPD ratio shows a
significant correlation with the sensitivity of fluoropyrimidine
analogues, such as 50-deoxy-5-fluorouridine (50-DFUR) and
capecitabine (Ishikawa et al, 1998; Terashima et al, 2002). Ishikawa
et al (1998) examined the relationships of tumour sensitivity to
UFT with the TP/DPD ratio in xenograft models. There was no
significant correlation between the TP/DPD ratio and tumour
sensitivities to UFT. This report supports our result that the TP/
DPD ratio was not related to the antitumour effect in terms of
tumour shrinkage and survival in patients treated with the UFT
and LV regimen. 50-DFUR and capecitabine metabolise to 5-FU by
TP and then the converted 5-FU is subsequently catabolised by
DPD (Ishikawa et al, 1998). The TP/DPD ratio might be the
predictor of antitumour effect only for 50-DFUR and capecitabine,
not UFT.
Generally, enzyme activities of both pyrimidine de novo
synthesis and the salvage pathway in cancer tissues are upregu-
lated more than those in normal tissues (Maehara et al, 1990;
Peters et al, 1991). We also found a moderately negative
correlation between DPD and OPRT gene expression. These data
reflect Isshi’s report that DPD enzyme activity correlates with
OPRT enzyme activity in human colorectal cancer tissues (r
 0.448, Po0.01) (Isshi et al, 2002). Orotate phosphoribosyl-
transferase plays a role in the de novo pyrimidine synthesis
pathway, which converts orotic acid to orotidine-50-monopho-
sphate (OMP) (Suchi et al, 1997). As mentioned above, DPD is
categorised into the enzyme of the pyrimidine salvage pathway.
Details of the underlying mechanisms remain unclear and further
investigations are needed to clarify this molecular event.
If OPRT and DPD are coregulated, there would be little or no
additional benefit for response prediction from measuring both
enzyme expressions. The correlation between OPRT and DPD gene
expressions was moderate (r  0.5299) and there were 12 cases
(34%) that had low OPRT/low DPD or high OPRT/high DPD gene
expressions. In all, 12 of 13 tumours with high OPRT and low DPD
responded to UFT and LV therapy, having a response rate of 92%,
but not all tumours with low OPRT or high DPD responded.
Furthermore, the OPRT/DPD ratio was the predictor of antitumour
effect to the UFT and LV regimen. UFT contains the 5-FU prodrug
tegafur, which is converted by the P450 drug-metabolising enzyme
in the liver (Kohne and Peters, 2000). The present study as well as
recent reports (Isshi et al, 2002; Fujii et al, 2003) disclosed that the
OPRT pathway was the most important to activate 5-FU among the
three pathways. Hence, the ratio of OPRT and DPD, which is the
rate-limiting enzyme of metabolism, was also evaluated. The
OPRT/DPD ratios were statistically higher in responding tumours
than in nonresponding ones and patients with high OPRT/DPD
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Figure 5 OPRT/DPD and TP/DPD ratios in terms of response. The
responding tumours had statistically higher OPRT/DPD ratios than the
nonresponding ones (P¼0.003). However, the TP/DPD ratio had no
statistical significance in terms of response.
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Figure 6 Correlation between prognosis and the expression of OPRT/
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Further studies are necessary to evaluate whether the OPRT/DPD
ratio could be adopted as a possible predictor for the effectiveness
of other fluoropyrimidine analogues.
In this study, UP gene expression had no predictive value for
UFT/LV therapy. This result conflicts with previous reports of a
positive relationship between UP expression and tumour sensitiv-
ity to 5-FU in mouse and rat cells (Schwartz et al, 1985; Cao et al,
2002). However, Cuq et al (2001) reported that UP overexpression
did not increase the 5-FU sensitivity of human breast cancer cell.
This discrepancy might be explained by species differences of UP
expressions. Uridine phosphorylase increased in tumour tissues of
mice and rats compared with human tissues, and the main enzyme
of pyrimidine nucleoside phosphorylase is UP in rodents and TP in
humans (Maehara et al, 1989).
Thymidylate synthase expression has the most evident value for
the prediction of antitumour effect by fluoropyrimidine (Adlard
et al, 2002). Previously, we reported that TS gene expression also
had a predictive value to evaluate the antitumour effect in the same
patient cohort (Ichikawa et al, 2003). As this study involved only a
small number of patients, we could not evaluate the predictive
value of TS when combined with DPD, OPRT, and TP. Large,
prospectively randomised translational research studies are needed
to apply predictive molecular markers in clinical practice, using
standardised and validated assays.
We found that OPRT gene expression and the ratio of OPRT
and DPD can be used to predict tumour shrinkage and survival
in response to UFT and LV chemotherapy. Our study is a first
step toward the goal of individualised cancer chemotherapy
based on the fluoropyrimidine-related molecular characte-
ristics of the tumour. However, the conclusions are drawn
from a retrospective study consisting of a limited number of
patients. Prospectively randomised translational treatment trials
are needed to confirm our results and to define the best OPRT
and OPRT/DPD cutoff points for each fluropyrimidine-based
chemotherapy.
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